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Accurate determination of the antibiotic susceptibility of patho-
gens is essential for both patient management and epidemiologic
purposes. Unfortunately, there are differences in methodology
(e.g. media, inoculum, incubation conditions) and interpreta-
tion (e.g. numerical values of breakpoint concentrations and
zone sizes) between recommendations approved by various
organizations. Results using different methods have not been
correlated for all antibiotics.
Such differences appear to be of particular importance in the
case of pneumococci, as incubation in the presence of CO2 is
recommended by some but not all testing protocols. For
example, incubation in CO2 is recommended by the NCCLS
and BSAC for agar diffusion [1,2], by the Swedish guidelines [3]
and for the E test [4]. On the other hand, incubation in air is
suggested by the NCCLS for broth dilution [5], and by BSAC
for agar dilution [6]. The European Committee [7] advises the
use of CO2 only when ‘necessary’, while French guidelines [8]
do not address this problem.
CO2 is a well recognized confounding factor in susceptibility
testing, as, among other factors, the reduction in pH it engen-
ders may signiﬁcantly alter the apparent activity of some anti-
biotics. Thus, ideally it should be used routinely only when
absolutely necessary for the growth of the organism being tested
(e.g. for gonococci), which, notwithstanding the recommenda-
tionsmentioned above, is not the case for pneumococci.We have
recently found (unpublished) that only six of 175 freshly isolated
strains of pneumococci (3.4%) were strictly capnophilic.
We wish to illustrate discrepancies that can arise between
results obtained using different methods, giving as an example
comparative data recently obtained with evernimicin, a mem-
ber of the orthosomycin family of polysaccharide antibiotics [9].
MICs determined by plate dilution were compared with results
of E tests, using different media and incubation conditions, as
recommended by the NCCLS, the BSAC and AB Biodisk (the
manufacturers of the E test). Evernimicin has been shown to
diffuse too poorly to be tested by the standard disk diffusion
method [10].
MICs of evernimicin (SCH 27899, kindly supplied by the
Schering Plough Research Institute) against 50 clinical isolates
of Streptococcus pneumoniae were determined by four different
methods: agar dilution, according to NCCLS and BSAC
recommendations, and E test using Mueller–Hinton agar
(MHA) and IsoSensitest agar (ISA). In addition, the effect of
CO2 on the activity of evernimicin was investigated by testing
20 of the strains on MHA incubated in CO2 (i.e. standard
NCCLS conditions) and in air. Results of E tests were read
using an endpoint of 80% inhibition, as recommended by
Marshall et al [11]. Media were obtained from Unipath Ltd,
Basingstoke, UK. The control strain was S. pneumoniae ATCC
49619, as recommended by the NCCLS [5].
Table 1 shows that MICs obtained using the BSAC method
were almost double those determined according to the NCCLS
protocol. This difference can be explained by the effect of
CO2—present in the test conducted following NCCLS guide-
lines, absent when using the BSACmethod. From Table 2 it can
be seen that under otherwise identical conditions, incubation in
CO2 causes a two-fold reduction in the MIC of evernimicin.
Marshall et al [11] and Jones and Barrett [12] have, respec-
tively, shown that MICs for pneumococci in MH medium
incubated in CO2 are virtually identical in broth and agar, and
our results (Table 1) agree very closely with those of the latter
workers.
The results of E tests in the different media (both carried out
in the presence of CO2) were almost identical, but consistently
lower than the respective results obtained by the dilution
method. A partial explanation of this may be that, as recom-
mended, E test endpoints were read at 80% inhibition, whereas
the plate MIC was read, as customary, at 100% inhibition.
However, there was little or no discrepancy between E test and
plate dilution results when staphylococci and enterococci were
tested in a similar manner (unpublished results), so this may be a
phenomenon peculiar to pneumococci.
It is not clear which of theMIC values obtained is ‘correct’ in
terms of prediction of therapeutic efﬁcacy. The results here
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indicate that testing pneumococci in the presence of CO2 will
overestimate the activity of evernimicin under normocapnic
conditions. Although the difference observed was only small
(2.4-fold in terms of the geometric mean Table 2), it may be of
relevance when considering therapy for, on the one hand,
pneumococcal pneumonia (where there will be hypercapnosis),
and, on the other hand, otitis media or meningitis, where there
is likely to be normocapnosis. There is clear evidence in the case
of aminoglycosides, for example, that decreased activity in the
presence of CO2 explains the need to use a larger dose when
treating chest infections [13].
We have previously found that CO2 alters the activity of
another novel antibiotic, linezolid, only against pneumococci
[14]. In view of this and the ﬁndings described above, it would
seem appropriate to include comparative studies of different
susceptibility testing methodologies at an early stage in the
assessment of a novel antibiotic.
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Table1 Activity of evernimicin against 50 strains of Streptococcus pneumoniae and control strain determined by four methods
MIC (mg/L)
Medium Method Range MIC50 MIC90 Geometric mean Control strain
a
Mueller^Hinton agar Dilution 0.03^0.13 0.13 0.13 0.09 0.06, 0.06, 0.06
E test 0.016^0.064 0.032 0.047 0.031 0.047, 0.047, 0.047
IsoSensitest agar Dilution 0.06^0.25 0.13 0.25 0.17 0.13, 0.13, 0.13
E test 0.016^0.13 0.032 0.064 0.036 0.047, 0.047, 0.032
aS. pneumoniaeAscc 49619.
Table2 Activity of evernimicin against 20 strains of Streptococcus pneumoniae: effect of incubation in carbon dioxide onMueller^Hinton agar
MIC (mg/L)
Incubation Range MIC50 MIC90 Geometricmean
Air 0.13^0.25 0.13 0.25 0.16
Carbon dioxide 0.03^0.13 0.06 0.13 0.068
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